NewsAccretion Pharmaceuticals Submits Structured Digital Database Compliance Certificate for FY Ended 31st March, 2026Accretion Pharmaceuticals Submits Structured Digital Database Compliance Certificate for FY Ended 31st March, 2026
Accretion Pharmaceuticals Limited submitted its Structured Digital Database Compliance Certificate to the National Stock Exchange of India Limited for the financial year ended 31st March, 2026. The certificate, issued by M/s. Sakhiya & Co., Practicing Company Secretaries, confirms adherence to Regulation 3(5) and 3(6) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The company successfully captured 2 required events during the quarter, with no non-compliance observed and no remedial actions necessary.
*this image is generated using AI for illustrative purposes only.
Accretion Pharmaceuticals Limited has filed its Structured Digital Database (SDD) Compliance Certificate with the National Stock Exchange of India Limited, pertaining to the financial year ended 31st March, 2026. The certificate was submitted on 7th May, 2026, by Company Secretary and Compliance Officer Roshni Shah, pursuant to Regulation 3(5) and 3(6) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
Certificate Issued by Practicing Company Secretaries
The SDD Compliance Certificate was issued by CS Nimish Sakhiya, Proprietor of M/s. Sakhiya & Co., Practicing Company Secretaries, based in Rajkot. The certificate was prepared on the basis of details and documents provided by the company and carries the ICSI Firm Unique Code S2019GJ689300 and ICSI Peer Review No. 4057/2023.
Key Compliance Parameters Confirmed
The certificate confirms that Accretion Pharmaceuticals has met all requisite compliance parameters under the PIT Regulations. The following aspects of SDD compliance were certified:
- The company has a Structured Digital Database in place
- Access controls exist to regulate who can access the SDD
- All Unpublished Price Sensitive Information (UPSI) disseminated in the previous quarter has been captured in the database
- The system has captured the nature of UPSI along with date and time
- The database is maintained internally with an audit trail
- The database is non-tamperable and capable of maintaining records for 8 years
Event Capture and Non-Compliance Status
The table below summarises the event capture and compliance status for the quarter ended 31st March, 2026:
| Parameter: | Details |
|---|---|
| Events Required to be Captured: | 2 |
| Events Actually Captured: | 2 |
| Non-Compliance Observed: | Not Applicable |
| Remedial Action Required: | Not Applicable |
The certifying company secretary confirmed that no non-compliance was observed during the quarter, and accordingly, no remedial actions were required.
Filing Details
The compliance certificate was digitally signed by both Roshni Shah, Company Secretary and Compliance Officer of Accretion Pharmaceuticals, and CS Nimish Sakhiya on 7th May, 2026. The submission was addressed to the Corporate Relations Department of the National Stock Exchange of India Limited.
Historical Stock Returns for Accretion Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.52% | +6.27% | +61.23% | +74.53% | +44.12% | +44.12% |
How does Accretion Pharmaceuticals' consistent SDD compliance track record compare to its peers in the Indian pharmaceutical sector, and could this strengthen investor confidence in the stock?
What types of Unpublished Price Sensitive Information were the 2 captured events likely related to, and could they signal upcoming corporate actions such as mergers, acquisitions, or new drug approvals?
As SEBI continues to tighten insider trading regulations, how might future amendments to the PIT Regulations 2015 impact the compliance burden for small and mid-cap pharmaceutical companies like Accretion Pharmaceuticals?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
